Breaking News, Collaborations & Alliances

SK pharmteco Doubles Viral Vector Production Capacity in Europe

Operation of the second facility to kick start in 2024.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

SK pharmteco, SK Inc.’s contract development manufacturing organization (CDMO) for pharmaceuticals, completed its second facility for cell and gene therapies (CGT) manufacturing in Europe. With this milestone, SK pharmteco is rapidly expanding its presence in the global market. SK pharmteco announced on June 22nd that Yposkesi, its commercial viral vector manufacturing subsidiary for CGTs in France, successfully completed the construction of its second industrial bioproduction site for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters